Innovation in pharmaceutical biotechnology: Comparing national innovation systems at the sectoral level

Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level

Volumn 9789264014046, Issue , 2006, Pages 1-187

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957746468     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1787/9789264014046-en     Document Type: Book

References (66)

1. Alliance Pharmaceutical Corp. (2003), "Phases of Product Development", www.allp.com/drug-dev.htm.
2. BPI (2003), Pharma Daten 2003, Berlin.
3. EFPIA (2001), "G10 Medicines High Level Group on Innovation and Provision of Medicines Consultation Paper - EFPIA Comments", www.efpia.org/4-pos/economic/g10.pdf.
4. EFPIA (2002), "The Pharmaceutical Industry in Figures", 2002 edition, Brussels, www.efpia.org/6-publ/Infigures2002.pdf.
5. Enzing, C.M., S. Kern and T. Riess (2002), "Case Study on Biotech Innovation Systems: Guidebook", TNO-STB/Fraunhofer-ISI, Delft/Karlsruhe.
6. European Generic Medicines Association (EGA) (2003), "Introduction" (Web page), www.egagenerics.com/members/ega.htm, accessed 30 July 2003.
7. Fraunhofer ISI (2004), "New Products and Services: Analysis of Regulations Shaping New Markets", Final Report to the European Commission DG Enterprise, Karlsruhe.
8. Gambardella, A., L. Orsenigo, and F. Pammolli (2000), "Global Competitiveness in Pharmaceuticals", European Commission, DG Enterprise, Brussels.
9. Human Genome Consortium (2001), "Initial Sequencing and Analysis of the Human Genome", Nature, 409, pp. 860-921.
10. Lienhardt, J. et al. (2003), "Statistics in Focus: High-tech Industries in the EU", Eurostat Web site, http://europa.eu.int/comm/eurostat/.
11. OECD (1999), Managing National Innovation Systems, OECD, Paris.
12. OECD (2002), Dynamising National Innovation Systems, OECD, Paris.
13. PhRMA (2003), "PhRMA Industry Profile 2003 - Appendix", Web document, www.phrma.org/publications/publications/profile02/APPENDIX.pdf.
14. Reiss, T. (2001), "Drug Discovery of the Future: The Implications of the Human Genome Project", Trends in Biotechnology, 19, pp. 496-499.
15. US Census Bureau (2001), "1997 Economic Census - Manufacturing: General Summary", Web document, www.census.gov/prod/ec97/97m31s-gs.pdf, accessed 12 August 2003.
16. Venter, G. et.al. (2001), "The Sequence of the Human Genome", Science, 291, pp. 1304-1451.
17. Mangamatin, V. et al. (2003), "Development of SMEs and Heterogeneity of Trajectories: The Case of Biotechnology in France", Research Policy, Vol. 32, pp. 621-638.
18. OECD (2002), Dynamising National Innovation Systems, OECD, Paris.
19. BioCentury (2003), Vol. 11, No. 44, 6 October, p. 15.
20. EVCA (1990-2003), Yearbooks, Brussels.
21. OECD (1994), The Measurement of Scientific and Technological Activities: Using Patent Data as Science and Technology Indicators - Patent Manual, OECD, Paris.
22. DiMasi, J.A., R.W. Hansen and H.G. Grabowski (2003), "The Price of Innovation: New Estimates of Drug Development Costs", Journal of Health Economics, 22, pp. 151-185.
23. OECD (1996), Globalisation of Industry: Overview and Sector Reports, OECD, Paris.
24. OECD (2001), New Patterns of Industrial Globalisation: Cross-border Mergers and Acquisitions and Strategic Alliances, Paris, OECD.
25. OECD (2003), OECD Science, Technology and Industry Scoreboard, OECD, Paris.
26. Senker, J., M. Brady and P. van Zwanenberg (2000), "European Biotechnology Innovation System: UK Report", EC TSER Contract No. SOE1-CT98-1117 (DG 12- SOLS), September.
27. UNCTAD (2000), World Investment Report 2000: Cross-border Mergers and Acquisitions and Development, United Nations, Geneva.
28. Ager, B. (2003), "Pricing Policy in Europe: Evolution and Assessment", 8ème Conférence Annuelle Pharmacie: Prix du Médicament, 2 July.
29. Beise, M. and K. Rennings (2003), "Lead Markets of Environmental Innovations: A Framework for Innovation and Environmental Economics", ZEW Discussion Paper 03-01.
30. Bibby, K., J. Davis and C. Jones, IMS Global Consulting (2003), "Biopharmaceuticals: Moving to Centre Stage", in 2003 BioPeople North American Biotechnology Industry and Suppliers' Guide, pp. 3-11.
31. European Commission (2003), "A Stronger European-based Pharmaceutical Industry for the Benefit of the Patient: A Call for Action", COM(2003) 383.
32. EFPIA (2003), "The Pharmaceutical Industry in Figures", 2003 edition, Brussels.
33. Farmaindustria (2002), La Industria Farmacéutica en Cifras, Madrid.
34. Gaskell, G. et al. (2000), "Biotechnology and the European Public", Nature Biotechnology, Vol. 18, September, pp. 935-938.
35. Hoban, T.J. (1999), "Consumer Acceptance of Biotechnology in the United States and Japan", Food Technology, Vol. 53, No. 5, pp. 50-53.
36. JPMA: Japan Pharmaceutical Manufacturers Association (2003), "Pharmaceutical Administration and Regulations in Japan", Tokyo, March.
37. Martikainen, J. and S. Rajaniemi (2002), "Drug Reimbursement Systems in EU Member States, Iceland and Norway", Social Security and Health Reports 54, The Social Insurance Institution, Helsinki.
38. Matsushima, S., and I. Miyamoto (2003), "Biotechnology-kanren sangyô" [Biotechnology-related industries], in A. Goto and H. Odagiri, eds. (2003), Sciencegata sangyô [Science-based Industries], NTT Shuppan, Tokyo.
39. Medical Research Council (n.d.), Research in Focus: Monoclonal Antibodies. What are Monoclonal Antibodies, London.
40. Meyer-Krahmer, F. and Reger (1999), "New Perspectives on the Innovation Strategies of Multinational Enterprises: Lessons for Technology Policy in Europe", Research Policy, Vol. 28, No. 7, pp. 751-776.
41. MindBranch, Inc. (2000). Patient Groups and the Global Pharmaceutical Industry, Urch Publishing Ltd., Washington.
42. Moors, E., C.M. Enzing, A. van der Giessen and R. Smits (2003), "User-Producer Interactions in Functional Genomics Innovations", Innovation: Management, Policy & Practice, Vol. 5/2-3, December, pp. 120-143.
43. Office of Industries, US International Trade Commission (1999), Staff Research Study 25: Review of Global Competitiveness in the Pharmaceutical Industry, Publication 3172, April.
44. PhARMA (2002), 2002 Biotechnology New Medicines in Development Survey 371, "Biotechnology Medicines in Testing Promise to Bolster the Arsenal against Disease", Pharmaceutical Research and Manufacturers of America, Washington, DC.
45. Research and Markets (2003), Biopharmaceuticals: Current Market Dynamics and Future Outlook, Dublin.
46. Senker, J. (2001), European Biotechnology Innovation System (EBIS): Analysis of the Biopharmaceuticals Sector", EC TSER Contract No. SOE1-CT98-1117 (DG 12-SOLS) Contribution to Work Package 4, June.
47. Senker, J., M. Brady and P. van Zwanenberg (2000), "European Biotechnology Innovation System: UK Report", EC TSER Contract No. SOE1-CT98-1117 (DG 12- SOLS), September.
48. Szymkowski, D.E. (2004), "Rational Optimization of Proteins as Drugs: A New Era of 'Medicinal Biology'", Drug Discovery Today, Vol. 9, No. 9, pp. 381-383.
49. VFA (2002), Auf einen Blick. Forschende Arzneimittelhersteller in Zahlen und Fakten, Berlin.
50. Enzing, C.M., J.N. Benedictus, E. Engelen-Smeets, J.M. Senker, P.A. Martin, T. Reiss, H. Schmidt, G. Assouline, P.B. Joly and L. Nesta (1999), "Inventory and Analysis of Biotech Programmes and Related Activities in All Countries Participating in the EU FP4 Biotechnology Programmes 1994-1998", TNO-STB/SPRU (UK)/ISI-FhG (BRD)/QAP Decision and INRA (FRA), published by the EU Publication Office under the title "Inventory of Public Biotechnology R&D in Europe, Vol. 1: Analytical Report" (EUR 18886/1), Luxembourg.
51. Enzing, C.M., S. Kern and T. Riess (2002), "Case Study on Biotech Innovation Systems: Guidebook", TNO-STB/Fraunhofer-ISI, Delft/Karlsruhe.
52. European Commission (2003), Biotechnology Innovation Scoreboard 2003, European Trend Chart on Innovation, EC Enterprise Directorate-General, Brussels, available at: Ftp://ftpnl.cordis.lu/pub/trendchart/reports/documents/report7.pdf.
53. Reiss, T., S. Hinze, I. Dominguez-Lacasa, V. Mangematin, C. Enzing, A. van der Giessen, S. Kern, J. Senker, J. Calvert, L. Nest and P. Patel (2004), Efficiency of Innovation Policies in High Technology Sectors in Europe (EPOHITE), European Communities, Luxembourg.
54. Cohen, W.M. and D.A. Levinthal (1990), "Absorptive Capacity: A New Perspective on Learning and Innovation", Administrative Science Quarterly, 35, pp. 128-152.
55. Dahlander, L. and M. McKelvey (2003), "Proximity as a Factor in Biotechnology Research and Development", Wirtschaftspolitische Blätter, 3.
56. Moors, E., C.M. Enzing, A. van der Giessen and R. Smits (2003), "User-Producer Interactions in Functional Genomics Innovations", Innovation: Management, Policy & Practice, Vol. 5/2-3, December, pp. 120-143.
57. Smith, K. (1997), "Economic Infrastructures and Innovation Systems", in C. Edquist (ed.), Systems of Innovation: Technologies, Institutions and Organisations, Cassell, London.
58. Von Hippel, E. (1978), "Successful Industrial Products from Customer Ideas", Journal of Marketing, January, pp. 39-49.
59. Von Hippel, E. (1988), The Sources of Innovation, Oxford.
60. Arrow, Kenneth J. (1962), "The Economic Implications of Learning by Doing", Review of Economic Studies, Vol. 29, pp. 155-173.
61. Arnold, E. (2004), "Evaluating Research and Innovation Policy: A Systems World Needs Systems Evaluations", Research Evaluation, Vol. 13, No. 1, pp. 3-17.
62. Arnold, E. and S. Kuhlman (2001), "RCN in the Norwegian Research and Innovation System", Background Report No. 12 in the evaluation of the Research Council of Norway, Royal Norwegian Ministry of Research, Education and Church Affairs, Oslo.
63. Haukness, J. and L. Norgren (1999), "Economic Rationales of Government Intervention in Innovation and the Supply of Innovation Related Services", STEP Report No. 8, Oslo.
64. Lengrand, L. and Associates (2002), "Innovation Tomorrow. Innovation Policy and the Regulatory Framework: Making Innovation an Integral Part of the Broader Structural Agenda", PREST (UK) - ANRT (F), Innovation Paper No. 28, European Commission, DG Enterprise.
65. OECD (1999), Managing National Innovation Systems, OECD, Paris.
66. OECD (2002), Dynamising National Innovation Systems, OECD, Paris.